SAN DIEGO, August 08, 2024 — Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media and buffers for the cell and gene therapy industry, proudly announces the launch of a novel platform to expedite the formulation and manufacture of custom media. This platform, called QuickStart Media™, is a groundbreaking addition to its comprehensive line of cell culture products and solutions and further demonstrates Nucleus Biologics’ expertise and dedication to the delivery of custom cell culture media, buffers, reagents, and services simpler and faster. [Read more…]
Regenerative Stem Cell Therapy as Treatment for Neck Pain
Neck pain is one of the most pervasive problems in the world today. At any given time, 10 percent of adults report a stiff neck, while X-rays show signs of osteoarthritis in as much as 50 percent of the population over 50. As though that wasn’t enough, 40 percent of males and almost 30 percent of females in the mid-50s and 60s exhibit problems with discs, the round cushioning devices that separate vertebrae. Needless to say, treatment for neck pain is a serious need.
While it doesn’t constitute a deadly disease, neck pain does have the power to negatively impact a person’s life every single day. It makes mobility challenging, hampers daily activities, dampens the pleasure of human touch or hugs, and generally reduces the quality of life. Up until now, medical approaches have included chiropractic care, heating and icing, over-the-counter medication use and surgery. As a rule, those solutions are either too limited or too extreme.
Now there’s a new treatment for neck pain in town: stem cells. These “master cells” have the ability to transform into bodily structures that otherwise would not rebuild, renew, and heal. This offers a very promising neck pain treatment. But what is it? And how does it work?
In this article:
Interview with Accellta’s Intellectual Property (IP) Officer, Eran Cohen
This is an follow-up to our interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
Organizations Who are Conducting Human Trials with iPSC-Derived Cellular Therapeutics
Induced pluripotent stem (iPS) cells are a type of stem cell that can be generated directly from adult cells. They were first developed in 2006 by Shinya Yamanaka and his team. iPS cells are engineered by reprogramming adult cells, such as skin cells, to revert to a pluripotent state, meaning they have the ability to differentiate into any cell type in the body. This reprogramming is typically achieved by introducing a combination of specific genes or gene factors into the adult cells, which resets their developmental clock. [Read more…]
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021
Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults
IND filing for OpCT-001 is planned for 2024
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 202
- Next Page »




